Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Dana-Farber researchers to present more than 40 studies at 2019 ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the 61st American Society of Hematology (ASH) Annual Meeting on December 7-10 in Orlando, Fla. Dana-Farber is home to one of the largest and most respected treatment centers for patients with disorders of the blood and bone marrow. ASH is the world's most comprehensive hematology event, attracting more than 25,000 hematology professionals from around the world.

Scientific updates to be presented at ASH reveal potentially practice changing findings related to stem cell transplant, multiple myeloma, and leukemia treatment. Notable oral presentations by Dana-Farber researchers include:

Title: Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Abstract: 48

Author:R. Coleman Lindsley, MD, PhD

Session time: Saturday, December 7, 8:45 a.m. EST


Title: AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo


Author: Yu-Tzu Tai, PhD

Session time: Saturday, December 7, 10:00 a.m.


Title: A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Abstract: 258

Author: Jacqueline Garcia, MD

Session time: Saturday, December 7, 3:15 p.m.


Title: Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Abstract: 580

Author: Mark Bustoros, MD

Session time: Monday, December 9, 7:45 a.m.


Title: Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Abstract: 775

Author: Reid W. Merryman, MD

Session time: Monday, December 9, 2:45 p.m.

Complete details on Dana-Farber’s activities at ASH are available online here.

For all ASH-related media inquiries, call or email Claire Monaghan, 617-632-5653,


Posted on November 26, 2019

  • Reid W. Merryman, MD
  • Research
  • Yu-Tzu Tai, PhD
  • R. Coleman Lindsley, MD, PhD
  • Jacqueline S. Garcia, MD
  • Stem Cell/Bone Marrow Transplant
  • Blood Disorders
  • Waldenström’s Macroglobulinemia
  • Myelodysplastic/Myeloproliferative Diseases
  • Multiple Myeloma
  • Hodgkin lymphoma
  • Lymphomas
  • Chronic Myelogenous - CML
  • Acute Myeloid - AML
  • Acute Lymphoblastic - ALL
  • Leukemias
  • Blood Cancer

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.